Skip to main content
. 2020 Feb 27;4(4):e10346. doi: 10.1002/jbm4.10346

Figure 2.

Figure 2

Change in lumbar spine TBS relative to baseline during ACTIVE (Abaloparatide Comparator Trial In Vertebral Endpoints) in patients with type 2 diabetes mellitus (T2DM) mean percent change from baseline in lumbar spine TBS in patients from ACTIVE with T2DM treated with placebo, abaloparatide, or teriparatide. Significant increases in TBS were seen with abaloparatide versus placebo (p < 0.01 at 6 months and p < 0.001 at 18 months) and teriparatide versus placebo (p < 0.05 at 6 months and p < 0.001 at 18 months). Error bars indicate 95% CIs.

* P<0.001 ABL vs PBO; † P<0.01 ABL vs PBO; ‡ P<0.001 TPTD vs PBO; P<0.05 TPTD vs PBO.

ABL, abaloparatide; PBO, placebo; TBS, trabecular bone score; TPTD, teriparatide.